A combination of sorafenib and nilotinib reduces the growth of castrate-resistant prostate cancer

A combination of sorafenib and nilotinib reduces the growth of castrate-resistant prostate cancer

Monica Archibald,1 Tara Pritchard,1 Hayley Nehoff,1 Rhonda J Rosengren,1 Khaled Greish,1,2 Sebastien Taurin1 1Department of Pharmacology and Toxicology, University of Otago, Dunedin, New Zealand; 2Aljawhara Centre for Molecular Medicine, Arabian Gulf University, Manama, Kingdom of Bahrain Abstract...

Full description

Bibliographic Details
Main Authors: Archibald M, Pritchard T, Nehoff H, Rosengren RJ, Greish K, Taurin S
Format: Article
Language:English
Published: Dove Medical Press 2016-01-01
Series:International Journal of Nanomedicine
Subjects:
sorafenib
nilotinib
castrate-resistant prostate cancer
tyrosine kinase inhibitors
nanomedicine
Online Access:https://www.dovepress.com/a-combination-of-sorafenib-and-nilotinib-reduces-the-growth-of-castrat-peer-reviewed-article-IJN

Internet

https://www.dovepress.com/a-combination-of-sorafenib-and-nilotinib-reduces-the-growth-of-castrat-peer-reviewed-article-IJN

Similar Items